- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Identifying Bronchiectasis: Key Clinical Presentations to Consider
Panagis Galiatsatos, MD, MHS, provides an overview of clinical presentations that prompt consideration of bronchiectasis in the differential diagnosis.
EP: 1.Overview of Bronchiectasis
EP: 2.Prognosis For Patients Diagnosed With Bronchiectasis
EP: 3.Indicators Leading to Bronchiectasis Testing and Diagnosis
EP: 4.Complications Associated With Bronchiectasis
EP: 5.Current Treatment Options For Bronchiectasis
EP: 6.Respiratory and Physical Therapists Contributing to Comprehensive Bronchiectasis Care
EP: 7.Key Areas of Research and Emerging Therapies In Bronchiectasis Treatment
EP: 8.Diagnosing and Understanding the Pathogenesis of Bronchiectasis
EP: 9.Improving Long-Term Outlook: CT Scans and Underdiagnosis of Bronchiectasis
EP: 10.Bronchiectasis Exacerbation Management
EP: 11.Social Burden and Goals of Therapy for Patients with Bronchiectasis
EP: 12.Patient Specific Factors: Guiding Treatment in Bronchiectasis
EP: 13.Individualized Therapy for Specific Infections Associated with Bronchiectasis
EP: 14.Other Challenges With Bronchiectasis and Key Takeaways
EP: 15.Identifying Bronchiectasis: Key Clinical Presentations to Consider
EP: 16.Differentiating Bronchiectasis from COPD and Understanding Exacerbations
EP: 17.Long-Term Impact of Bronchiectasis Exacerbations: Disease Progression, Patient Outcomes, and Economic Burden
EP: 18.Managing Bronchiectasis: Treatment Goals, Outcome Measures, and Clinical Decision Resources
EP: 19.Addressing Knowledge Gaps and Treatment Strategies in Bronchiectasis
EP: 20.Challenges and Future Directions in Bronchiectasis Management
Video content above is prompted by the following question:
- Based on your experience, what clinical presentations prompt consideration of bronchiectasis in the differential diagnosis?
Camlipixant May Benefit Patients With High-Burden RCC
June 25th 2025A phase 2a trial of camlipixant, a selective P2X3 receptor antagonist, found that while the drug did not significantly reduce cough frequency in the overall population with refractory chronic cough, it produced meaningful improvements in patients with a higher baseline cough burden.
Read More
Preventing Respiratory Illness and Death Through Tighter Air Quality Standards
June 1st 2021On this episode of Managed Care Cast, a research scholar at the Marron Institute of Urban Management at New York University discusses the latest findings in the Health of the Air report, which was presented at the recent American Thoracic Society 2021 International Conference.
Listen
